Amgen is a big company that makes medicine. Some people who know a lot about companies and money think it will do well in the future. They have different opinions on how much money Amgen could make. The price of the part of Amgen that people can buy and sell, called stocks, is going down a little bit right now. But some people still think it's a good idea to buy these stocks because they believe Amgen will make more money in the future. Read from source...

1. The title is misleading and clickbaity: "A Look at What the Big Money is Thinking" suggests that the article will reveal some insights or secrets from wealthy investors or institutional shareholders, but in reality, it only presents a few analysts' opinions and ratings.
2. The article lacks originality and depth: most of the information provided could be easily found on Yahoo Finance or Google Finance, and there is no attempt to analyze the data, compare with competitors, or explain the implications for Amgen's strategy, growth, or profitability.
3. The article is too focused on short-term performance: while it mentions some key indicators like trading volume, price, RSI, and earnings report date, it does not provide any context or trend analysis to show how these variables are changing over time or what they mean for Amgen's future prospects.
4. The article uses vague and subjective terms: words like "approaching", "may be", "persists", "cautious", and "maintaining" are not precise or quantifiable, and do not help the reader understand the reasoning behind the analysts' ratings or opinions. They also create a sense of uncertainty and confusion, which could affect the reader's decision-making process.
5. The article does not disclose any conflicts of interest: it mentions four different analysts from UBS, RBC Capital, TD Cowen, and an unknown source, but it does not inform the reader about their credentials, track record, or possible biases that could influence their ratings or recommendations.
6. The article ends abruptly and without a conclusion: it cuts off in the middle of a sentence, leaving the reader hanging and wondering what was going to be said next. This creates a bad impression and lowers the credibility of the author and the source.

1. Option 1: Buy AMGN at the current market price ($275.77) and hold for the next earnings report, expecting a positive surprise and an increase in stock price. Risk: If the earnings report is disappointing or matches expectations, the stock price may not increase significantly, resulting in a modest gain or loss.

2. Option 2: Buy AMGN at a 10% discount ($248.77) and hold for the next earnings report, expecting a positive surprise and an increase in stock price. Risk: If the earnings report is disappointing or matches expectations, the stock price may not increase significantly, resulting in a modest gain or loss. However, by purchasing at a lower price, you are reducing your overall risk exposure.

3. Option 3: Sell AMGN short at its current market price ($275.77) and set a stop-loss at $280 to limit potential losses. Risk: If the earnings report is positive and exceeds expectations, the stock price may increase significantly, resulting in a substantial loss. However, if the earnings report is disappointing or matches expectations, you may benefit from the downside, but there is also a risk of a rebound in the stock price.

4. Option 4: Sell AMGN short at a 10% discount ($248.77) and set a stop-loss at $253 to limit potential losses. Risk: If the earnings report is positive and exceeds expectations, the stock price may increase significantly, resulting in a substantial loss. However, if the earnings report is disappointing or matches expectations, you may benefit from the downside, but there is also a risk of a re